World J Gastroenterol. 2008 June 21; 14(23): 3609-3615.
Published online 2008 June 21. doi: 10.3748/wjg.14.3609.
Minimal hepatic encephalopathy matters in daily life
Jasmohan S Bajaj.
Jasmohan S Bajaj, Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, United States
Author contributions: Bajaj JS contributed all to this paper.
Correspondence to: Jasmohan S Bajaj, MBBS, MD, MS, Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, United States. jasmohan@gmail.com
Telephone: +1-414-4566825
Fax: +1-414-4566214
Received February 27, 2008; Revised March 23, 2008; Accepted March 30, 2008;
Abstract
Minimal hepatic encephalopathy is a neuro-cognitive dysfunction which occurs in an epidemic proportion of cirrhotic patients, estimated as high as 80% of the population tested. It is characterized by a specific, complex cognitive dysfunction which is independent of sleep dysfunction or problems with overall intelligence. Although named “minimal”, minimal hepatic encephalopathy (MHE) can have a far-reaching impact on quality of life, ability to function in daily life and progression to overt hepatic encephalopathy. Importantly, MHE has a profound negative impact on the ability to drive a car and may be a significant factor behind motor vehicle accidents. A crucial aspect of the clinical care of MHE patients is their driving history, which is often ignored in routine care and can add a vital dimension to the overall disease assessment. Driving history should be an integral part of care in patients with MHE. The lack of specific signs and symptoms, the preserved communication skills and lack of insight make MHE a difficult condition to diagnose. Diagnostic strategies for MHE abound, but are usually limited by financial, normative or time constraints. Recent studies into the inhibitory control and critical flicker frequency tests are encouraging since these tests can increase the rates of MHE diagnosis without requiring a psychologist. Although testing for MHE and subsequent therapy is not standard of care at this time, it is important to consider this in cirrhotics in order to improve their ability to live their life to the fullest.
Keywords: Minimal hepatic encephalopathy, Quality of life, Driving impairment, Diagnosis, Therapy, Prognosis
INTRODUCTION
Minimal hepatic encephalopathy is a neuro-cognitive dysfunction which occurs in an epidemic proportion of cirrhotic patients, estimated as high as 80% of the population tested. It is characterized by a specific, complex cognitive dysfunction which is independent of sleep dysfunction or problems with overall intelligence[1]. Although named “minimal”, minimal hepatic encephalopathy (MHE) can have a far-reaching impact on quality of life, ability to function in daily life and progression to overt hepatic encephalopathy (OHE)[2]. Importantly, MHE has a profound negative impact on the ability to drive a car and may be a significant factor behind motor vehicle accidents. Research in this field is expanding rapidly, but little consensus has emerged regarding standard diagnostic strategies or therapeutic options[3]. The current editorial will focus on the relevance of MHE as an important clinical entity that is ready for evaluation and regular detection not only in research centers but in routine hepatology practice.
PREVALENCE AND IMPORTANCE
With improving management of cirrhotic patients, including those with end-stage liver disease, the neuro-psychological care of these patients is being recognized as an unmet need[46]. The importance of MHE has been recognized by hepatologists worldwide and of late an explosion of research in this field has occurred[78].
Since its first description in the 1970s, MHE has been diagnosed in several countries around the world at a rate of 30%-80%[910]. The European experience has shown a high prevalence of MHE in patients who are predominantly non-alcoholic and without any psychoactive drug use[1112]. The diagnostic methodologies were a combination of neuro-psychometric and neuro-physiologic testing strategies[1113]. In the United States, the rate of MHE in several research series has been reported to be 60%-80%, again using a combination of psychometric and neuro-physiologic techniques[1415].
Experience in Asian countries, especially India, Japan and China, has reconfirmed the high prevalence using locally modified tools[101622]. The diagnostic tools were adapted to the local language and to include illiterate subjects[1719]. The patient population in these series has included a higher number of patients with viral hepatitis compared to Western series[2122].
CHARACTERIZATION OF MINIMAL HEPATIC ENCEPHALOPATHY
The importance of MHE lies in its specific deficits. As outlined by Weissenborn et al, patients with MHE have defects in attention, vigilance and orientation[23]. These attention deficits in turn lead to learning impairment and difficulties in working memory[1224]. Psychometric testing in patients with MHE has consistently demonstrated a preservation of overall IQ compared to age-matched controls, indicating that the defects are restricted to certain aspects only[11]. Patients with cirrhosis can also exhibit motor impairments that include Parkinsonian features and features of hepatic myelopathy[2526]. However, these motor deficits are not included in the typical impairment seen in MHE.
Importantly, deficits in MHE do not extend to the verbal and communication spheres[11]. Similar to OHE patients, there is evidence that patients with MHE have poor insight into their psychometric impairments[2729]. The preservation of communication skills, lack of symptoms and the poor insight make MHE patients a difficult group to identify with simple questioning in the office.
CONTRIBUTION OF CONCOMITANT DISEASES TO MHE
Patients with specific etiologies of cirrhosis are more likely to exhibit psychometric impairment, specifically chronic hepatitis C. Investigations in the chronic hepatitis C infected groups (both with and without cirrhosis) show a worse psychometric performance compared to patients without chronic hepatitis C in selected studies[3033]. However, other studies have not demonstrated a difference in psychometric performance of cirrhotics with chronic hepatitis C compared to those without it[3034]. In addition, a recent detailed study before and after interferon therapy in chronic hepatitis C cirrhotics failed to find an improvement or deterioration during and after therapy completion[35].
Diabetes mellitus is an important correlate of patients with cirrhosis, with the increasing importance of non-alcoholic steatohepatitis, and is also correlated with chronic hepatitis C in the general population[36]. Diabetes mellitus, possibly due to its adverse effect on gastrointestinal motility, has been associated with hepatic encephalopathy[3437].
Most studies of MHE exclude patients with alcoholic liver disease; therefore, excluding patients with chronic hepatitis C and diabetes mellitus will seriously hinder the generalization of the study. Therefore, a subgroup analysis of chronic hepatitis C and diabetes mellitus within the cirrhosis group or regression adjustment would be necessary for MHE investigation.
CONCOMITANT SLEEP DISTURBANCES
Hepatic encephalopathy is associated with adverse effects on the sleep-wake cycle, especially causing fragmentation of sleep, sleep deprivation and reports of drowsiness during the day[38]. Sleep deprivation per se can result in impaired psychometric test performance and as is evidenced in the case of obstructive sleep apnea, and can independently lead to poor driving outcomes[39]. There is debate whether the MHE-associated psychometric impairment is partly due to the inherent sleep-wake cycle disturbances in this condition. Validated sleep and quality of life questionnaire such as Sickness Impact Profile (SIP) sleep scales, Pittsburgh Sleep Quality index and Epworth Sleepiness scale evaluation demonstrate a worse sleep quality and effect on quality of life in patients with MHE[173840]. Steindl et al demonstrated a disrupted melatonin cycle in patients with cirrhosis and MHE which was independent of psychometric performance[41]. However, reports have demonstrated that cirrhotics with MHE and sleep disruption do not have worse psychometric performance compared to those who do not have sleep disruption[384243]. This implies that although there is a significant disruption of the sleep-wake and circadian rhythm in patients with MHE, this phenomenon co-exists with the psychometric impairment and is not the cause of it.
QUALITY OF LIFE AND MHE
Quality of life is an essential assessment component of patients with chronic diseases. Issues pertaining to quality of life are also central to most patient complaints in cirrhosis[44]. Groeneweg et al studied the Sickness Impact Profile (SIP) in a cohort of cirrhotics being tested for MHE (Medical Outcomes Trust, Boston, MA)[40]. The SIP consists of 136 items which questions patients about 12 sections; sleep and rest, eating, work, home management, recreation and pastimes, ambulation, mobility, body care and movement (the last three generate a physical sub score), social interaction, alertness behavior, emotional behavior, and communication (comprising the psychosocial sub score). All scales were significantly impaired in MHE patients compared to others. A recent study by Prasad et al confirmed these findings in MHE patients in all spheres apart from communication, which was similar between patients with or without MHE[17]. Impaired quality of life has also been demonstrated using the Short Form 36 (SF-36) in MHE populations in several studies across the world[4546].
Short form-36 (SF-36) is a 36-part questionnaire that has been used in several studies to characterize chronic liver disease and the chronic liver disease questionnaire has also been used in patients with liver disease[4447].
The SIP is an extensive survey which requires several minutes to complete, in contrast to the relatively short SF-36. The SF-36, therefore, may be a better tool for clinical practice. However, since quality of life changes in MHE are subtle, the SIP is perhaps the questionnaire better suited for research studies since it can differentiate between small changes in several aspects of QOL.
WORK CAPACITY AND MHE
The specific nature of cognitive dysfunction in MHE results in a disproportionate impairment of workers engaged in “blue-collar” professions compared to “white-collar” professionals. This is essential to remember because cirrhotics engaged in professions that require constant vigilance and coordination, e.g. machinery operators and drivers are affected by MHE more severely compared to those who have predominantly verbal and intellectual functions, such as administrative and company executives[29]. Therefore, MHE not only has the potential to endanger the patients and co-workers during complex occupational tasks, it also can adversely affect their socio-economic status by interfering with work performance[48].
MHE AND PROGRESSION TO OVERT HEPATIC ENCEPHALOPATHY
Overt hepatic encephalopathy portends a poor prognosis and overall survival[4950]. Patients with MHE have a higher likelihood of development of OHE[14495152]. Specific subgroups that are more likely to progress to OHE are males, those with a history of OHE, those with alcoholic etiology of cirrhosis and those with varices[195354]. Positive responders to the glutamine tolerance test are also more likely to develop OHE[53]. It is not clear, however, which individual MHE patient will go on to develop OHE. The relative contributions of precipitating factors, such as gastrointestinal bleeding, for OHE development in the context of MHE versus no MHE have also not been fully elucidated. Therefore, patients with MHE may be a subgroup requiring close follow-up clinically for OHE development, especially when potential precipitating factors are encountered.
MHE AND DRIVING CAPABILITY
The ability to drive a motor vehicle requires coordination of visual, auditory and vestibular inputs and has the potential to be impaired by metabolic encephalopathies[55].
MHE affects attention, psychomotor function and working memory, all of which are essential for safe driving[56]. Most studies of driving ability using on-road driving tests have demonstrated that MHE patients have significant defects in reaction time, resulting in their pronouncement as unsafe drivers in studies from Germany and Japan[4957]. Wein et al studied the driving ability and rating of driving behavior of 44 patients with cirrhosis using instructors masked to their status. Fourteen of these patients had been diagnosed with MHE[58]. Results showed that patients with MHE required interventions by the driving instructor to prevent an accident at a rate 10 times higher compared to those with MHE and controls. Specific driving behaviors were also rated worse in patients with MHE, especially car handling, adaptation, cautiousness and maneuvering[58].
Another essential skill required for safe driving is navigation, which ensures that the subject is in the right place at the right time[55]. Given the working memory abnormalities in cirrhotic patients, the study of navigation in MHE is important[24]. Our group recently published a study evaluating the performance of cirrhotics to age and education-matched controls on a driving simulator. Navigation skills in MHE are adversely affected[59]. All patients underwent a driving simulation which also included a navigation task. This task consisted of driving through a “virtual city” and illegal turns off the marked path were recorded. There was a significantly higher rate of illegal turns in the MHE group compared to those without MHE and controls. Illegal turns were proportionate to impairment in psychometric performance in cirrhotic group[59]. Therefore, driving difficulties in patients with MHE are likely multi-dimensional and includes impairment in reaction time and navigation skills.
DRIVING OUTCOMES IN PATIENTS WITH CIRRHOSIS AND MHE
Traffic accidents are one the leading causes of death worldwide, especially in young adults, the most productive age group of any society. It is important to determine whether patients with MHE also have poor driving outcomes compared to those without MHE and controls. This would be essential in formulating public health decisions regarding licensing and therapy for MHE. A study published by our group sent an anonymous driving outcome questionnaire to controls, cirrhotics tested for MHE and cirrhotics not tested for MHE due to concurrent psychoactive drug use[60]. As many as 33% of MHE patients reported having a traffic accident or violation within the last year compared to only 4% of MHE negative patients and 12% of the patients using psychoactive drugs. When 5 year data were analyzed a significant majority of MHE patients (53%) reported a traffic accident or violation compared to only 23% of MHE negative patients and 22% of those on psychoactive drugs. This is even more significant since none of the MHE patients were drinking alcohol. On multi-variate analysis, MHE emerged as the sole factor associated with traffic violations [odds ratio 6.0 (CI 1.2-31.3)], motor vehicle accidents [odds ratio 7.3 (CI 2.1-33.2)] and both [odds ratio 7.6 (CI 1.5-37.3)][60]. However, despite these striking numbers, there is still the need to analyze driving data prospectively using identified records before making specific recommendations regarding driving capability[3].
Patients with cirrhosis have a poor prognosis after trauma and surgery, especially with increasing Child-Pugh score[61]. A combination of coagulation impairment, sepsis and hepatic dysfunction has been noted as contributing factors to this worse prognosis[61]. A study of a large inpatient sample from the United States showed that patients with cirrhosis who were involved in a motor vehicle crash had a higher mortality than those who were admitted for motor vehicle crashes only[62]. Despite a younger average age, patients with cirrhosis and crash had a similar mortality compared to those admitted with cirrhosis only. Hospitalization charges and inpatient stay were also significantly higher in cirrhotics with crash compared to patients admitted for cirrhosis only and those admitted for motor vehicle accidents only. On multi-variate regression within the patients admitted with motor vehicle accidents, age > 65 years and cirrhosis were the variables most significantly associated with mortality[62].
Therefore, not only are patients with MHE more likely to get into an accident, they are also more likely to die from it and utilize greater resources as a result of the accident. All these factors make it essential for a clinician to take a driving history when evaluating patients for cirrhosis and chronic liver disease.
MHE: INSIGHT INTO THE DISEASE PROCESS AND DRIVING SKILLS
Insight into personal deficits is essential in patients in order to seek medical intervention. Anosognosia, defined as the unawareness of a disease, is a key component of the disease process in several metabolic and vascular cerebral disorders[6364]. This phenomenon is clearly observed in patients with OHE, in which it is the persons in the environment who detect changes in the patients’ sensorium rather than the patient[27]. A recent report extended this lack of insight into driving impairment. This study demonstrated that patients with MHE rated themselves as significantly better drivers compared to those without MHE and controls when they were evaluated by independent observers[28]. Therefore, similar to patients with OHE, it may be important to elicit a complete driving history and assessment from relatives familiar with the MHE patients’ driving rather than relying on the patients’ history alone.
THE HISTORY NOT TAKEN: DRIVING HISTORY
The standard of care of patients with cirrhosis without any ongoing acute issues is focused on strategies aimed to prevent decompensation. These strategies are aimed at reducing mortality and morbidity from a liver disease standpoint. However, as evidenced by recent reports, patients with cirrhosis and MHE also are at risk for developing morbidity and mortality behind the steering wheel[5860]. An objective driving history, including confirmation from the local supervisory agency, and corroboration of driving skills by relatives is also an essential aspect of patient care. The driving history to the clinical history would arguably be a vital addition to the overall understanding of the disease severity from a clinical and psychosocial view in cirrhosis.
TESTING FOR MHE DURING CLINIC VISITS
Although the majority of surveyed hepatologists in Spain and the United States agreed that MHE was a significant problem requiring testing, the minority were able to actually test for MHE as part of their clinical practice[78]. Main barriers to MHE testing were inability to get tests paid for by insurance, adding time to clinic visits and lack of standardized norms for the United States[8].
The psychometric battery recommended by the Working Group on Hepatic Encephalopathy is the PSE-syndrome test published by Weissenborn et al[211]. This test battery, although quite efficient in diagnosing MHE, requires a psychologist and valid population norms. The difficulty of applying these tests in the United States is the lack of background population norms and the need for a licensed psychologist to order and administer these tests. In addition, these are still not routinely covered by private health care insurance. These logistic barriers have effectively prevented routine clinic diagnosis of MHE.
The AASLD survey also highlighted the need for simpler and rapid testing that can take the place of cumbersome and copyrighted psychometric testing[8]. The inhibitory control and the critical flicker frequency have emerged as tests that can be applied in clinical practice without the need for psychological expertise[313142065]. However, detailed validation studies are still underway for these tests.
POPULATION TO BE TESTED
Patients with cirrhosis who are ambulatory and capable of independent living are the ones most affected by MHE and should definitely be tested. Previous recommendations have been split regarding the specific population to be targeted for testing. Ortiz et al and Stewart et al have specifically recommended certain patient populations be tested[148]. Psychometric performance can be affected by current alcohol use, use of psychoactive drugs and pre-existing neurological disorders[11]. In cirrhotics who do not fulfill these criteria, it is in the best interest of the patient to be offered testing at the initial visit regardless of their subsequent activities. There is no consensus regarding the frequency of testing, but experience has shown relative similarity in psychometric scores at 6 mo intervals in the absence of acute clinical and neurological events such as development of OHE[19].
THERAPY FOR MHE
Treatment of MHE improves psychometric performance and quality of life[1617].
A recent consensus conference promulgated lactulose as the first choice of therapy for MHE in concordance with the previous study data and the AASLD survey[38]. However, whether this would have any effect on development of OHE, driving capability or overall survival remains to be investigated. Since driving and psychometric impairments are highly correlated, it is reasonable to expect that driving performance would also improve after MHE therapy.
However, the adherence rate of lactulose in patients with OHE is low; therefore, to expect an MHE patient, who does not have any specific symptoms and lacks insight into their problems, to be adherent on a medication that could cause diarrhea and flatulence is difficult[366]. Therefore, alternatives to lactulose have also been studied for MHE. Liu et al showed that fiber and fiber with probiotics improved psychometric function and importantly the Child class of patients[21]. Similar studies have been published using various formulations of probiotics with good improvement in psychometric tests[6771]. Our group has recently completed a randomized control trial of a probiotic yogurt that resulted in a significant reversal of MHE in the yogurt-randomized group compared to the group randomized to no treatment[72]. The adherence was excellent and none of the yogurt-treated group developed OHE. Although probiotics are attractive options that spare the patients from the poor palatability of lactulose, difficulties in the availability and the standardization of probiotic organisms remain. However, these preliminary data suggests that dietary intervention may be considered in addition to probiotics for amelioration of MHE.
Therefore, although treatment options for MHE are evolving, it is still important to test patients to offer them the available therapeutic options.
CONCLUSION
MHE is an epidemic cognitive dysfunction in patients with cirrhosis which is gaining importance in clinical and research spheres due to improved survival in cirrhotic patients.
MHE patients exhibit a specific cognitive impairment that negatively impacts their driving capability and work performance and importantly is not evident to the patients themselves.
A crucial aspect of the clinical care of MHE patients is their driving history, which is often ignored in routine care and can add a vital dimension to the overall disease assessment. Driving history should be an integral part of care in patients with MHE.
The lack of specific signs and symptoms, the preserved communication skills and lack of insight make MHE a difficult condition to diagnose.
Diagnostic strategies for MHE abound, but are usually limited by financial, normative or time constraints. Recent studies into the inhibitory control and critical flicker frequency tests are encouraging since these tests can increase the rates of MHE diagnosis without requiring a psychologist.
Although testing for MHE and subsequent therapy is not standard of care at this time, it is important to consider this in cirrhotics in order to improve their ability to live their life to the fullest.
Footnotes
Peer reviewer: Giovanni Tarantino, MD, Professor, Department of Clinical and Experimental Medicine, Federico II University Medical School, VIA S. PANSINI, 5, Naples 80131, Italy
S- Editor Li DL L- Editor Rippe RA E- Editor Liu Y
References
1.
Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol. 2005;42 Suppl:S45-S53.
2.
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721.
3.
Mullen K, Ferenci P, Bass NM, Leevy CB, E . K. An Algorithm for the Management of Hepatic Encephalopathy. Seminars in Liver Disease. 2007;27:32-48.
4.
Qadri AM, Ogunwale BO, Mullen KD. Can we ignore minimal hepatic encephalopathy any longer?. Hepatology. 2007;45:547-548.
5.
Talwalkar JA, Kamath PS. Influence of recent advances in medical management on clinical outcomes of cirrhosis. Mayo Clin Proc. 2005;80:1501-1508.
6.
Noble JA, Caces MF, Steffens RA, Stinson FS. Cirrhosis hospitalization and mortality trends, 1970-87. Public Health Rep. 1993;108:192-197.
7.
Vergara-Gomez M, Flavia-Olivella M, Gil-Prades M, Dalmau-Obrador B, Cordoba-Cardona J. [Diagnosis and treatment of hepatic encephalopathy in Spain: results of a survey of hepatologists]. Gastroenterol Hepatol. 2006;29:1-6.
8.
Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States: An AASLD survey. Hepatology. 2007;45:833-834.
9.
Rikkers L, Jenko P, Rudman D, Freides D. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology. 1978;75:462-469.
10.
Saxena N, Bhatia M, Joshi YK, Garg PK, Tandon RK. Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. J Gastroenterol Hepatol. 2001;16:322-327.
11.
Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001;34:768-773.
12.
Ortiz M, Cordoba J, Jacas C, Flavia M, Esteban R, Guardia J. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol. 2006;44:104-110.
13.
Romero-Gomez M, Cordoba J, Jover R, del Olmo JA, Ramirez M, Rey R, de Madaria E, Montoliu C, Nunez D, Flavia M. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45:879-885.
14.
Bajaj JS, Saeian K, Verber MD, Hischke D, Hoffmann RG, Franco J, Varma RR, Rao SM. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol. 2007;102:754-760.
15.
Meyer T, Eshelman A, Abouljoud M. Neuropsychological changes in a large sample of liver transplant candidates. Transplant Proc. 2006;38:3559-3560.
16.
Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, Toda G, Kobayashi K, Muto Y, Tsujii T. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology. 1997;26:1410-1414.
17.
Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45:549-559.
18.
Li YY, Nie YQ, Sha WH, Zeng Z, Yang FY, Ping L, Jia L. Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China. World J Gastroenterol. 2004;10:2397-2401.
19.
Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16:531-535.
20.
Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol. 2007;47:67-73.
21.
Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39:1441-1449.
22.
Kato A, Kato M, Ishii H, Ichimiya Y, Suzuki K, Kawasaki H, Yamamoto SI, Kumashiro R, Yamamoto K, Kawamura N. Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteria-multicenter collaborative study in Japanese. Hepatol Res. 2004;30:71-78.
23.
Weissenborn K, Giewekemeyer K, Heidenreich S, Bokemeyer M, Berding G, Ahl B. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis. 2005;20:359-367.
24.
Weissenborn K, Heidenreich S, Giewekemeyer K, Ruckert N, Hecker H. Memory function in early hepatic encephalopathy. J Hepatol. 2003;39:320-325.
25.
Joebges EM, Heidemann M, Schimke N, Hecker H, Ennen JC, Weissenborn K. Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. J Hepatol. 2003;38:273-280.
26.
Bechar M, Freud M, Kott E, Kott I, Kravvic H, Stern J, Sandbank U, Bornstein B. Hepatic cirrhosis with post-shunt myelopathy. J Neurol Sci. 1970;11:101-107.
27.
Weissenborn K. Clinical features of hepatic encephalopathy. In:Zakim D, Boyer TD.,editors.Hepatology. 4th ed. Philadelphia: WB Saunders; 2003.pp.431-444.
28.
Bajaj JS, Saeian K, Hafeezullah M, Hoffmann RG, Hammeke TA. Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clinical Gastroenterology and Hepatology. 2008;6:1135-1139.
29.
Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001;16:37-41.
30.
Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008;53:307-321.
31.
Citro V, Milan G, Tripodi FS, Gennari A, Sorrentino P, Gallotta G, Postiglione A, Tarantino G. Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. J Gastroenterol. 2007;42:79-82.
32.
Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, Ahl B, Manns MP, Boker KW. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41:845-851.
33.
Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003;9:847-854.
34.
Kalaitzakis E, Olsson R, Henfridsson P, Hugosson I, Bengtsson M, Jalan R, Bjornsson E. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver Int. 2007;27:1194-1201.
35.
Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok AS, Kronfol Z, Padmanabhan L. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology. 2007;45:1154-1163.
36.
Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-599.
37.
Sigal SH, Stanca CM, Kontorinis N, Bodian C, Ryan E. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol. 2006;101:1490-1496.
38.
Cordoba J, Cabrera J, Lataif L, Penev P, Zee P, Blei AT. High prevalence of sleep disturbance in cirrhosis. Hepatology. 1998;27:339-345.
39.
Engleman HM, Hirst WS, Douglas NJ. Under reporting of sleepiness and driving impairment in patients with sleep apnoea/hypopnoea syndrome. J Sleep Res. 1997;6:272-275.
40.
Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, Schalm SW. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45-49.
41.
Steindl PE, Finn B, Bendok B, Rothke S, Zee PC, Blei AT. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann Intern Med. 1995;123:274-277.
42.
Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol. 2007;102:744-753.
43.
Montagnese S, Middleton B, Skene DJ, Morgan MY. Sleep-wake abnormalities do not correlate with neuropsychiatric performance in patients with cirrhosis (abstract). Hepatology. 2008;46:563A.
44.
Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, Loguercio C, Apolone G, Niero M, Abbiati R. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120:170-178.
45.
Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci. 2003;48:1622-1626.
46.
Bao ZJ, Qiu DK, Ma X, Fan ZP, Zhang GS, Huang YQ, Yu XF, Zeng MD. Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy. World J Gastroenterol. 2007;13:3003-3008.
47.
Ferrer M, Cordoba J, Garin O, Olive G, Flavia M, Vargas V, Esteban R, Alonso J. Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl. 2006;12:95-104.
48.
Stewart CA, Smith GE. Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol. 2007;4:677-685.
49.
Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25 Suppl 1:3-9.
50.
Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodes J. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30:890-895.
51.
Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96:2718-2723.
52.
Saxena N, Bhatia M, Joshi YK, Garg PK, Dwivedi SN, Tandon RK. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver. 2002;22:190-197.
53.
Romero-Gomez M, Grande L, Camacho I, Benitez S, Irles JA, Castro M. Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. J Hepatol. 2002;37:781-787.
54.
Hartmann IJ, Groeneweg M, Quero JC, Beijeman SJ, de Man RA, Hop WC, Schalm SW. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000;95:2029-2034.
55.
Maguire EA, Burgess N, Donnett JG, Frackowiak RS, Frith CD, O'Keefe J. Knowing where and getting there: a human navigation network. Science. 1998;280:921-924.
56.
Evans L. The dominant role of driver behavior in traffic safety. Am J Public Health. 1996;86:784-786.
57.
Watanabe A, Tuchida T, Yata Y, Kuwabara Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis. 1995;10:239-248.
58.
Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004;39:739-745.
59.
Bajaj JS, Hafeezullah M, Hoffmann RG, Varma RR, Franco J, Binion DG, Hammeke TA, Saeian K. Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology. 2008;47:596-604.
60.
Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol. 2007;102:1903-1909.
61.
Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, Talwalkar JA, Kim WR, Kamath PS. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132:1261-1269.
62.
Bajaj JS, Ananthakrishnan AN, McGinley E, Hoffmann RG, Brasel KJ. Deleterious impact of cirrhosis on outcomes after motor vehicle crashes using the Nationwide Inpatient Sample. Am J Gastroenterol. 2008;130:1674-1681.
63.
Ries ML, Jabbar BM, Schmitz TW, Trivedi MA, Gleason CE, Carlsson CM, Rowley HA, Asthana S, Johnson SC. Anosognosia in mild cognitive impairment: Relationship to activation of cortical midline structures involved in self-appraisal. J Int Neuropsychol Soc. 2007;13:450-461.
64.
Starkstein SE, Jorge R, Mizrahi R, Adrian J, Robinson RG. Insight and danger in Alzheimer's disease. Eur J Neurol. 2007;14:455-460.
65.
Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology. 2002;35:357-366.
66.
Conn H. In Hepatic Encephalopathy: Management with lactulose and related carbohydrates. Illinois: Medi-Ed Press; 1988.
67.
Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2007;52:3259-3265.
68.
Boca M, Vyskocil M, Mikulecky M, Ebringer L, Kolibas E, Kratochvil'ova H, Buzgova D. [Complex therapy of chronic hepatic encephalopathy supplemented with probiotic: comparison of two studies]. Cas Lek Cesk. 2004;143:324-328.
69.
Macbeth WA, Kass EH, Mcdermott WV Jr. Treatment of hepatic encephalopathy by alteration of intestinal flora with lactobacillus acidophilus. Lancet. 1965;1:399-403.
70.
Uribe M, Dibildox M, Malpica S, Guillermo E, Villallobos A, Nieto L, Vargas F, Garcia Ramos G. Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus. Gastroenterology. 1985;88:901-907.
71.
Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis. 2004;5:64-67.
72.
Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Franco J, Varma RR, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103:1707-1715.